Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Shivam Tyagi

The author works as a Correspondent with BW Businessworld

Latest Articles By Shivam Tyagi

Valuation A Complicated Game, Startups, Tech Cos Visualising Future: Thyrocare's Creator, Dr Velumani

Shivam Tyagi

Startups and tech companies across industries are being valued today at mountain-high valuations, with investors sprinkling the dry powder and founders aiming for volumes, scale and consolidation and not minding the losses. But the industry today is also not new to certain post-listing debacles of tech companies and a recent valuation turnaround of a health-tech company PharmEasy lowering its valuations by 90 per cent to fund its debt

Read More

Extend GST Waiver To All Rare Diseases Drugs: Industry Body & Patient Groups Highlight Gaps

Shivam Tyagi

While The GST Council’s decision was well received across the spectrum, pharmaceutical companies, industry bodies and patient advocacy groups have argued that the exemption should be applicable to all rare disease drugs and should not be only restricted when imported for personal use as this can pose multiple challenges for patients

Read More

Healthcare's Rising Carbon Footprint

Shivam Tyagi

According to a 2019 report by Health Care Without Harm (HCWH), the global healthcare sector’s climate footprint is equivalent to 4.4 per cent of global net emissions, contributing around 2 gigatonnes of carbon dioxide into the environment

Read More

Novo Nordisk’s Obesity Drug Pipeline Stacked Up For Next 15-20 Yrs: John C Dawber, GBS

Shivam Tyagi

In India, the Danish drugmaker Novo Nordisk is the market leader and presently meets over 60 per cent of the country’s insulin supply. Speaking to BW Businessworld in an exclusive interaction, John C. Dawber, CVP and MD, Global Business Services talks about the company’s GLP1 growth story, the market of obesity drugs and their safety profile, building capacities and the company's future ambitions in India

Read More

Exclusive: Existing Legal Framework Needs To Be More Robust For Healthcare's Carbon Footprint

Shivam Tyagi

Experts believe with access to health rising post-pandemic in India, the carbon footprint is also slated to rise simultaneously. The report by HWH also affirms this by showing a strong correlation between a nation’s health spending and its carbon footprint. India at present is witnessing a huge capacity build in the healthcare sector with the healthcare providers expanding their bed capacities on account of increasing bed occupancies in the hospitals

Read More

The Arrival Of Home Healthcare On D-Street

Shivam Tyagi

Healthvista India will soon make its debut on the Indian exchanges, becoming the first company of the $6 billion home healthcare industry, which is touted as one of the sunrise sectors

Read More

Homing In On Growth

Shivam Tyagi

Healthvista India’s debut on the Indian exchanges will be the first from the $6-billion home healthcare stable

Read More

Health Ministry Denies Direct CoWIN Data Breach, Directs CERT-In To Probe

Shivam Tyagi

On Monday, The Union Health Ministry said that it has requested the Indian Computer Emergency Response Team (CERT-In) to look into the CoWIN data breach reported in the media and submit a report adding that an additional internal exercise has also been initiated to review the existing security measures of CoWIN

Read More

India In Dire Need Of Stem Cell Donations, What Is The Need? Why Should You Donate? All You Need To Know

Shivam Tyagi

India is facing a tough challenge in sourcing donors for stem cell transplants that prove as a saviour for many patients suffering from various types of blood disorders like leukaemia, thalassemia and aplastic anaemia among others. As per reports, India registers over 1,00,000 patients every year who are tackling different blood disorders. Out of this, the doctors say, 10 to 15 per cent of patients end up requiring stem cell transplants which can save their lives in majority of the cases

Read More

Biocon Investing Heavily In Peptides, Potent Oncology APIs: MD & CEO, Siddharth Mittal

Shivam Tyagi

Biocon’s MD and CEO, Siddharth Mittal in a post-annual results interaction with BW Healthcare World stated that, “As we move forward, we see a huge potential in peptides. It is a growing segment where the big shift is being seen with companies like Novo Nordisk or Eli Lilly moving their focus from insulins to GLP1 drugs and what used to be USD 20-30 billion insulin market is now actually projected to be over USD 100 billion GLP1 market"

Read More